Tony Cruz
About Tony Cruz
Tony Cruz - President of Transition Therapeutics
Tony Cruz holds the position of President at Transition Therapeutics. Transition Therapeutics is a prominent biopharmaceutical company dedicated to the development of advanced therapies. Cruz has been with Transition Therapeutics since its inception, having played a pivotal role in establishing the company's direction and strategy from the very beginning.
CEO of Transition Therapeutics and Industry Leadership at OPKO Health, Inc.
In June 2017, Tony Cruz joined OPKO Health, Inc. as the CEO of Transition Therapeutics Corp., ULC. His extensive experience in the biopharmaceutical industry has been instrumental in guiding the company's development and strategic initiatives. Cruz's leadership positions have consistently demonstrated his ability to drive innovation and growth within the sector.
Co-Founder and Major Contributions at Angiotech Pharmaceuticals Inc.
Tony Cruz co-founded Angiotech Pharmaceuticals Inc., known for the development of the Taxol-coated stent for cardiovascular restenosis, which was marketed by Boston Scientific. At Angiotech, he served as Vice-President of Research and was a member of the Board of Directors, playing a crucial role in the company’s research and product development activities.
Scientific Leadership and Funding Initiatives at the Canadian Arthritis Network (CAN)
Tony Cruz was a founding member and served as the Scientific Director and CEO of the Canadian Arthritis Network (CAN). Under his leadership, CAN successfully raised approximately $30 million to support research funding within the Network. His role was essential in forging partnerships that helped advance the Network’s mission in the biotech sector.
Academic Career and Contributions to Research
From 1987 to 2008, Tony Cruz had an accomplished academic career with over 150 publications. He was a senior scientist at Mount Sinai Hospital and served as a Professor at the University of Toronto until 2008. His academic and research contributions have been significant in advancing knowledge within the biopharmaceutical and medical research communities.